Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Tumor, KRAS Mutation”

157 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 157 results

Not applicableLooking for participantsNCT04151342
What this trial is testing

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Who this might be right for
CancerMalignancies MultipleMalignant Solid Tumor+7 more
University Health Network, Toronto 5,500
Early research (Phase 1)Looking for participantsNCT06484556
What this trial is testing

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Who this might be right for
Tumor, Solid
Tao Zhang 9
Early research (Phase 1)Ended earlyNCT06130254
What this trial is testing

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Who this might be right for
Advanced Solid TumorNon-small Cell Lung Cancers
M.D. Anderson Cancer Center 1
Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Looking for participantsNCT06244771
What this trial is testing

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Who this might be right for
Advanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid Tumor+5 more
Frontier Medicines Corporation 403
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Early research (Phase 1)Active Not RecruitingNCT07474168
What this trial is testing

T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Who this might be right for
Tumor
Zhejiang University 9
Early research (Phase 1)Not Yet RecruitingNCT07014878
What this trial is testing

DCTY1102 Injection in Participants With Advanced Solid Tumors

Who this might be right for
Colorectal CancerLung CancerPancreatic Cancer
Beijing DCTY Biotech Co.,Ltd. 18
Testing effectiveness (Phase 2)Ended earlyNCT04165031
What this trial is testing

LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerColorectal Cancer
Eli Lilly and Company 5
Testing effectiveness (Phase 2)UnknownNCT04073680
What this trial is testing

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Who this might be right for
Breast CancerEndometrial CancerLung Cancer+2 more
Petra Pharma 60
Early research (Phase 1)Looking for participantsNCT06625775
What this trial is testing

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 392
Early research (Phase 1)Ended earlyNCT04249843
What this trial is testing

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Who this might be right for
Solid TumorB-Raf Mutation-Related Tumors
MapKure, LLC 109
Testing effectiveness (Phase 2)Looking for participantsNCT05410145
What this trial is testing

D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Who this might be right for
KRAS P.G12C
D3 Bio (Wuxi) Co., Ltd 442
Early research (Phase 1)Study completedNCT06117371
What this trial is testing

Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Who this might be right for
Advanced or Metastatic Solid TumorKRAS G12C Mutation
BeBetter Med Inc 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT06385678
What this trial is testing

HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 47
Early research (Phase 1)UnknownNCT05768321
What this trial is testing

Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumors
GenEros Biopharma Hangzhou Ltd 70
Early research (Phase 1)Looking for participantsNCT07456046
What this trial is testing

D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

Who this might be right for
KRAS P.G12D
D3 Bio (Wuxi) Co., Ltd 42
Early research (Phase 1)Ended earlyNCT04892017
What this trial is testing

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Deciphera Pharmaceuticals, LLC 91
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Next Page